CLAIMS

1. A pharmaceutical composition, comprising:

two anti-chondrogensis agents.

2. The pharmaceutical composition of claim 1, wherein the anti-chondrogenesis agent is an anti-muscarinic agent.

3. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent is atropine.

4. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent comprises about 0.001% to about 1% by weight atropine.

5. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent comprises about 0.005% to about 0.05% by weight atropine.

6. The pharmaceutical composition of claim 1, wherein the anti-chondrogensis agent is a non-steroidal anti-inflammatory drug (NSAID).

7. The pharmaceutical composition of claim 6, wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.

8. The pharmaceutical composition of claim 6, wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac.

9. The pharmaceutical composition of claim 6, wherein the NSAID comprises about

0.01% to about 0.2% by weight diclofenac.

10. The use of a pharmaceutical composition comprising one or more anti-chondrogensis agents in the manufacture of a medicament for the treatment of myopia.

11. The use of claim 10, wherein the anti-chondrogenesis agent is NSAID.

12. The use of claim 11, wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.

13. The use of claim 11, wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac.

14. The use of claim 11, wherein the NSAID comprises about 0.01% to about 0.2% by weight diclofenac.

15. The use of claim 10, wherein the anti-chondrogenesis agent is an anti-muscarinic agent.

16. The use of claim 15, wherein the anti-muscarinic agent is about 0.001% to about 1% by weight atropine.

17. The use of claim 15, wherein the anti-muscarinic agent is about 0.005% to about 0.05% by weight atropine.

CLAIMS

1. A pharmaceutical composition, comprising:

about 0.001 % to about 1% by weight atropine; and

about 0.01% to about 1% by weight nonsteroidal anti-inflammatory drug (NSAID).

2. The pharmaceutical composition of claim 1, wherein said atropine is about 0.005% to about 0.05% by weight.

3. The pharmaceutical composition of claim 1, wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.

4. The pharmaceutical composition of claim 3, wherein the NSAID is 0.05% to about 1% by weight Ketorolac.

5. The pharmaceutical composition of claim 3, wherein the NSAID is about 0.01% to about 0.2% by weight diclofenac.

6. The use of a pharmaceutical composition comprising an NSAID in the manufacture of a medicament for the treatment of myopia.

7. The use of claim 6, wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.

8. The use of claim 7, wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac.

9. The use of claim 7, wherein the NSAID comprises about 0.01% to about 0.2% by weight diclofenac.

10. The use of claim 6, further comprising about 0.001% to about 1% by weight atropine.

11. The use of claim 10, further comprising about 0.005% to about 0.05% by weight.

12. The use of a pharmaceutical composition comprising an NSAID in the manufacture of a medicament for reducing chondrogenesis.

13. The use of claim 12, wherein the NSAID is is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.

14. The use of a pharmaceutical composition comprising an anti-muscarinic agent in the manufacture of a medicament for inhibiting chondrogenesis.

15. The use of claim 14, wherein the anti-muscarinic agent is atropine.